GSK-3 Inhibitors: A New Class of Drugs for Alzheimer's Disease Treatment.

Alzheimer Disease / drug therapy Glycogen Synthase Kinase 3 / antagonists & inhibitors Humans Phosphorylation tau Proteins / metabolism
Alzheimer's disease GSK-3 GSK-3 inhibitors Tau neurodegenerative diseases protein kinase. β-amyloid

Journal

Current drug targets
ISSN: 1873-5592
Titre abrégé: Curr Drug Targets
Pays: United Arab Emirates
ID NLM: 100960531

Informations de publication

Date de publication:
2021
Historique:
received: 28 08 2020
revised: 26 10 2020
accepted: 28 10 2020
pubmed: 19 1 2021
medline: 30 11 2021
entrez: 18 1 2021
Statut: ppublish

Résumé

Alzheimer's disease (AD), a chronic neurodegenerative disease, is the most common form of dementia that causes cognitive function impairment, including memory, thinking, and behavioral changes that ultimately lead to death. The overactivation of GSK-3, an enzyme from the proline/serine K

Identifiants

DOI: 10.2174/1389450122666210114095307 PMID: 33459229
pubmed: 33459229
pii: CDT-EPUB-113299
doi: 10.2174/1389450122666210114095307
doi:

Substances chimiques

tau Proteins 0
Glycogen Synthase Kinase 3 EC 2.7.11.26

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1725-1737

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Dilipkumar Pal (D)

Department of Pharmaceutical Sciences, Guru Ghasidas Viswavidyalaya (A Central University), Bilaspur, Chhattisgarh, 495009, India.

Souvik Mukherjee (S)

Department of Pharmaceutical Sciences, Guru Ghasidas Viswavidyalaya (A Central University), Bilaspur, Chhattisgarh, 495009, India.

In-Ho Song (IH)

Institute of Applied Chemistry and Department of Chemistry, Hallym University, Chuncheon 200702, Korea.

Satish B Nimse (SB)

Institute of Applied Chemistry and Department of Chemistry, Hallym University, Chuncheon 200702, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › GSK-3 Inhibitors: A New Class of Drugs for...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Proline-directed protein kinases › Glycogen Synthase Kinase 3 › GSK-3 Inhibitors: A New Class of Drugs for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › GSK-3 Inhibitors: A New Class of Drugs for...
questionsmedicales.fr › Métabolisme › Phosphorylation › GSK-3 Inhibitors: A New Class of Drugs for...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines associées aux microtubules › Protéines tau › GSK-3 Inhibitors: A New Class of Drugs for...